Loading…
No business profile yet.
Size Apnimed (APMD) is a United States Health Care company (Biotechnology) with a market value of $629M, the 2560th largest of 3,117 United States companies the cockpit tracks. Shares closed at $15.10 on 6 Nov 2026.
Growth Revenue grew 380.1% over the last twelve months (peer median +7.9%); the operating margin is -139.9% (peer median -172.3%).
Valuation It trades at 20.3× enterprise value to sales against a peer median of 4.0× (4th most expensive of 13).
Capital Return on invested capital runs 46.5 points below its cost of capital (18.2% WACC).
Short interest Short interest is 4.3% of the free float (15 Oct 2026).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | $38.5M | $8.01M | $0 | $1.00M |
| Revenue growth | — | +380% | — | -100% | — |
| Gross profit | n/a | $31.8M | $4.64M | -$1,000 | n/a |
| EBITDA | n/a | -$53.8M | -$114M | -$48.5M | -$26.5M |
| Net income | n/a | -$128M | -$111M | -$80.2M | -$26.2M |
| Free cash flow | n/a | -$77.8M | -$110M | $25.4M | -$26.1M |
| Capital expenditure | n/a | $0 | $70,000 | $47,000 | $0 |
| Total debt | $80.3M | $41.5M | $1.09M | $0 | $109,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | APMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.1% | -10.5% | 7th lowest of 21 |
| Distance from 52-week high | -57.2% | -44.7% | 6th lowest of 21 |
| Revenue growth (TTM) | +380.1% | +7.9% | 3rd highest of 12 |
| Operating margin | -139.9% | -172.3% | 7th highest of 13 |
| EV / Sales | 20.3× | 4.0× | 4th most expensive of 13 |
| ROIC minus cost of capital | -46.5 pp | -27.1 pp | 5th highest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | 20.3× | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 1.6× | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | 2.0× | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | 2.7× | -8.3% | -1.3% |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a | n/a |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | 3.9× | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 4.1× | 35.4% | +27.2% |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 11.2× | 40.0% | +143.5% |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | 3.9× | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 4.7× | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | 25.7× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 2.1× | n/a | n/a |
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | 625.6× | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $554M | n/a | n/a | n/a | n/a | n/a | n/a |